Review



rabbit anti pd l1 antibody  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bioss rabbit anti pd l1 antibody
    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Rabbit Anti Pd L1 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti pd l1 antibody/product/Bioss
    Average 94 stars, based on 8 article reviews
    rabbit anti pd l1 antibody - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling"

    Article Title: Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling

    Journal: Materials Today Bio

    doi: 10.1016/j.mtbio.2025.102749

    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of PD-L1 (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Figure Legend Snippet: In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of PD-L1 (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Techniques Used: In Vitro, Immunofluorescence, Staining, Expressing, Control

    In vivo immune activation of Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence staining of HMGB1 (A, red) and CRT (B, red) in tumor tissues following various treatments. Blue: DAPI; scale bars: 100 μm. (n = 5). ( C, D ) Immunofluorescent staining of CD206 (C, green) and CD86 (D, green) in tumor sections. Blue: DAPI; scale bars: 100 μm. (n = 5). ( E ) Immunofluorescence staining of PD-L1 expression (red) in tumors across treatment groups. Blue: DAPI; scale bars: 100 μm. (n = 5). ( F, G ) Flow cytometry analysis of MHC-II expression (F) and CD80 + +CD86 + populations (G) in DCs from spleens. (n = 5). ( H ) Immunofluorescence co-staining of CD4 (green) and CD8 (red) in tumor tissues. Blue: DAPI; scale bars: 100 μm. (n = 5). Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Figure Legend Snippet: In vivo immune activation of Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence staining of HMGB1 (A, red) and CRT (B, red) in tumor tissues following various treatments. Blue: DAPI; scale bars: 100 μm. (n = 5). ( C, D ) Immunofluorescent staining of CD206 (C, green) and CD86 (D, green) in tumor sections. Blue: DAPI; scale bars: 100 μm. (n = 5). ( E ) Immunofluorescence staining of PD-L1 expression (red) in tumors across treatment groups. Blue: DAPI; scale bars: 100 μm. (n = 5). ( F, G ) Flow cytometry analysis of MHC-II expression (F) and CD80 + +CD86 + populations (G) in DCs from spleens. (n = 5). ( H ) Immunofluorescence co-staining of CD4 (green) and CD8 (red) in tumor tissues. Blue: DAPI; scale bars: 100 μm. (n = 5). Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Techniques Used: In Vivo, Activation Assay, Immunofluorescence, Staining, Expressing, Flow Cytometry



    Similar Products

    rabbit anti pd l1 antibody  (Bioss)
    94
    Bioss rabbit anti pd l1 antibody
    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Rabbit Anti Pd L1 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti pd l1 antibody/product/Bioss
    Average 94 stars, based on 1 article reviews
    rabbit anti pd l1 antibody - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    human pd l1 protein  (Sino Biological)
    95
    Sino Biological human pd l1 protein
    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Human Pd L1 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human pd l1 protein/product/Sino Biological
    Average 95 stars, based on 1 article reviews
    human pd l1 protein - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    pd-l1 t-hank  (ImmunityBio Inc)
    90
    ImmunityBio Inc pd-l1 t-hank
    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Pd L1 T Hank, supplied by ImmunityBio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd-l1 t-hank/product/ImmunityBio Inc
    Average 90 stars, based on 1 article reviews
    pd-l1 t-hank - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    pd l1 monoclonal antibody  (Proteintech)
    96
    Proteintech pd l1 monoclonal antibody
    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Pd L1 Monoclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd l1 monoclonal antibody/product/Proteintech
    Average 96 stars, based on 1 article reviews
    pd l1 monoclonal antibody - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    pdl1  (Sino Biological)
    95
    Sino Biological pdl1
    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Pdl1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pdl1/product/Sino Biological
    Average 95 stars, based on 1 article reviews
    pdl1 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    anti mouse pd l1 b7 h1 antibody  (MedChemExpress)
    94
    MedChemExpress anti mouse pd l1 b7 h1 antibody
    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Anti Mouse Pd L1 B7 H1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse pd l1 b7 h1 antibody/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    anti mouse pd l1 b7 h1 antibody - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    p99145  (MedChemExpress)
    94
    MedChemExpress p99145
    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    P99145, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p99145/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    p99145 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    murine pd l1  (Sino Biological)
    94
    Sino Biological murine pd l1
    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Murine Pd L1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine pd l1/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    murine pd l1 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    human pd l1  (Sino Biological)
    94
    Sino Biological human pd l1
    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Human Pd L1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human pd l1/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    human pd l1 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    anti mouse pd l1 pe  (Thermo Fisher)
    94
    Thermo Fisher anti mouse pd l1 pe
    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
    Anti Mouse Pd L1 Pe, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse pd l1 pe/product/Thermo Fisher
    Average 94 stars, based on 1 article reviews
    anti mouse pd l1 pe - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of PD-L1 (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Journal: Materials Today Bio

    Article Title: Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling

    doi: 10.1016/j.mtbio.2025.102749

    Figure Lengend Snippet: In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of PD-L1 (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Article Snippet: Alexa Fluor® 594 AffiniPure Goat Anti-Rabbit IgG (H + L) (Cat. No. 111-585-003, dilution: 1:250) was sourced from Jackson ImmunoResearch Inc. Rabbit anti-CD86 antibody (Cat. No. WL05184, dilution: 1:200), rabbit anti-iNOS antibody (Cat. No. WL0992a, dilution: 1:200), rabbit anti-CD206 antibody (Cat. No. WL06177, dilution: 1:200), and fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit IgG (H + L) (Cat. No. WLA032, dilution: 1:200) were purchased from Wanlei Bio-Tech Co., Ltd. Rabbit anti-PD-L1 antibody (Cat. No. bs-1103R, dilution: 1:250) was obtained from Beijing Bioss Biotechnology Co., Ltd. PerCP/Cyanine5.5 anti-mouse CD45 Recombinant Antibody (Cat. No. 157612, dilution: 1:200), PE anti-mouse CD11c Antibody (Cat. No. 117308, dilution: 1:200), APC anti-mouse CD86 Antibody (Cat. No. 159216, dilution: 1:200), FITC anti-mouse CD80 Antibody (Cat. No. 104706, dilution: 1:200), PE/Cyanine7 anti-mouse I-A b Antibody (Cat. No. 116420, dilution: 1:200), Zombie R718TM Fixable Viability Kit (Cat. No. 423116, dilution: 1:200), FITC anti-mouse CD3 Antibody (Cat. No. 100204, dilution: 1:100), PE anti-mouse CD4 Antibody (Cat. No. 100408, dilution: 1:200), APC/Cyanine7 anti-mouse CD8a Antibody (Cat. No. 100714, dilution: 1:200), APC anti-mouse/human CD11b Antibody (Cat. No. 101212, dilution: 1:200), APC/FireTM 750 anti-mouse F4/80 Antibody (Cat. No. 123152, dilution: 1:200), PE/DazzleTM 594 anti-mouse CD206 (MMR) Antibody (Cat. No. 141732, dilution: 1:200), and PE/Cyanine7 anti-mouse CD86 Antibody (Cat. No. 159208, dilution: 1:200) were purchased from BioLegend.

    Techniques: In Vitro, Immunofluorescence, Staining, Expressing, Control

    In vivo immune activation of Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence staining of HMGB1 (A, red) and CRT (B, red) in tumor tissues following various treatments. Blue: DAPI; scale bars: 100 μm. (n = 5). ( C, D ) Immunofluorescent staining of CD206 (C, green) and CD86 (D, green) in tumor sections. Blue: DAPI; scale bars: 100 μm. (n = 5). ( E ) Immunofluorescence staining of PD-L1 expression (red) in tumors across treatment groups. Blue: DAPI; scale bars: 100 μm. (n = 5). ( F, G ) Flow cytometry analysis of MHC-II expression (F) and CD80 + +CD86 + populations (G) in DCs from spleens. (n = 5). ( H ) Immunofluorescence co-staining of CD4 (green) and CD8 (red) in tumor tissues. Blue: DAPI; scale bars: 100 μm. (n = 5). Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Journal: Materials Today Bio

    Article Title: Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling

    doi: 10.1016/j.mtbio.2025.102749

    Figure Lengend Snippet: In vivo immune activation of Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence staining of HMGB1 (A, red) and CRT (B, red) in tumor tissues following various treatments. Blue: DAPI; scale bars: 100 μm. (n = 5). ( C, D ) Immunofluorescent staining of CD206 (C, green) and CD86 (D, green) in tumor sections. Blue: DAPI; scale bars: 100 μm. (n = 5). ( E ) Immunofluorescence staining of PD-L1 expression (red) in tumors across treatment groups. Blue: DAPI; scale bars: 100 μm. (n = 5). ( F, G ) Flow cytometry analysis of MHC-II expression (F) and CD80 + +CD86 + populations (G) in DCs from spleens. (n = 5). ( H ) Immunofluorescence co-staining of CD4 (green) and CD8 (red) in tumor tissues. Blue: DAPI; scale bars: 100 μm. (n = 5). Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

    Article Snippet: Alexa Fluor® 594 AffiniPure Goat Anti-Rabbit IgG (H + L) (Cat. No. 111-585-003, dilution: 1:250) was sourced from Jackson ImmunoResearch Inc. Rabbit anti-CD86 antibody (Cat. No. WL05184, dilution: 1:200), rabbit anti-iNOS antibody (Cat. No. WL0992a, dilution: 1:200), rabbit anti-CD206 antibody (Cat. No. WL06177, dilution: 1:200), and fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit IgG (H + L) (Cat. No. WLA032, dilution: 1:200) were purchased from Wanlei Bio-Tech Co., Ltd. Rabbit anti-PD-L1 antibody (Cat. No. bs-1103R, dilution: 1:250) was obtained from Beijing Bioss Biotechnology Co., Ltd. PerCP/Cyanine5.5 anti-mouse CD45 Recombinant Antibody (Cat. No. 157612, dilution: 1:200), PE anti-mouse CD11c Antibody (Cat. No. 117308, dilution: 1:200), APC anti-mouse CD86 Antibody (Cat. No. 159216, dilution: 1:200), FITC anti-mouse CD80 Antibody (Cat. No. 104706, dilution: 1:200), PE/Cyanine7 anti-mouse I-A b Antibody (Cat. No. 116420, dilution: 1:200), Zombie R718TM Fixable Viability Kit (Cat. No. 423116, dilution: 1:200), FITC anti-mouse CD3 Antibody (Cat. No. 100204, dilution: 1:100), PE anti-mouse CD4 Antibody (Cat. No. 100408, dilution: 1:200), APC/Cyanine7 anti-mouse CD8a Antibody (Cat. No. 100714, dilution: 1:200), APC anti-mouse/human CD11b Antibody (Cat. No. 101212, dilution: 1:200), APC/FireTM 750 anti-mouse F4/80 Antibody (Cat. No. 123152, dilution: 1:200), PE/DazzleTM 594 anti-mouse CD206 (MMR) Antibody (Cat. No. 141732, dilution: 1:200), and PE/Cyanine7 anti-mouse CD86 Antibody (Cat. No. 159208, dilution: 1:200) were purchased from BioLegend.

    Techniques: In Vivo, Activation Assay, Immunofluorescence, Staining, Expressing, Flow Cytometry